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Study objectives: Patients with chronic obstructive pulmonary disease (COPD) have low exercise 
capacity and low content of high energetic phosphates in their skeletal muscles. The aim of the 
present study was to investigate whether creatine supplementation together with exercise training 
may increase physical performance compared with exercise training in patients with COPD. 
Design: In a randomized, double-blind, placebo-controlled study, 23 patients with COPD (forced 
expiratory volume in one second [FEV1] < 70% of predicted) were randomized to oral creatine 
(n = 13) or placebo (n = 10) supplementation during an 8-week rehabilitation programme includ-
ing exercise training. Physical performance was assessed by Endurance Shuttle Walking Test 
(ESWT), dyspnea and leg fatigue with Borg CR-10, quality of life with St George’s Respiratory 
Questionnaire (SGRQ). In addition, lung function test, artery blood gases, grip strength test, 
muscle strength and fatigue in knee extensors were measured. 
Results: COPD patients receiving creatine supplementation increased their average walking 
time by 61% (ESWT) (p < 0.05) after the training period compared with 48% (p = 0.07) in 
the placebo group. Rated dyspnea directly after the ESWT decreased signiﬁ  cantly from 7 to 5 
(p < 0.05) in the creatine group. However, the difference between the groups was not statisti-
cally signiﬁ  cant neither in walking time nor in rated dyspnea. Creatine supplementation did 
not increase the health related quality of life, lung function, artery blood gases, grip strength 
and knee extensor strength/fatigue. 
Conclusions: Oral creatine supplementation in combination with exercise training showed no 
signiﬁ  cant improvement in physical performance, measured as ESWT, in patients with COPD 
compared with exercise training alone. 
Keywords: COPD, oral creatine supplementation, physical training
Introduction
Patients with chronic obstructive pulmonary disease (COPD) are limited by dyspnea, 
especially during physical activities (Marcel 1989). As a consequence the patients avoid 
activities resulting in further impairment of the patients’ physical condition (Olopade 
et al 1992). Progression of the disease is associated with increased dyspnea, decreased 
physical performance, skeletal muscular weakness, and high hospitalization rates. All 
have a negative impact on quality of life (McSweeny et al 1982). 
COPD is a disease with effects both in the lungs and organs outside the lungs. For 
instance skeletal muscle dysfunction, weight loss, cardiovascular and nervous system 
abnormalities, and osteoporosis are common systemic manifestations of COPD. It is 
therefore of great importance that therapy for COPD should treat the multicomponent 
nature of the disease (Agusti 2005). Pulmonary rehabilitation programmes for COPD 
patients improve the physical performance and the quality of life and are nowadays a 
cornerstone in the treatment of patients with COPD (Wijkstra et al 1994; Donner and 
Muir 1997). International Journal of COPD 2006:1(4) 446
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The immediate energy source for a muscle contraction is 
adenosine triphosphate (ATP) which is resynthesized from 
creatine phosphate (Soderlund and Hultman 1986). Creatine 
is a naturally occurring compound in the body and is also 
found in meat and some ﬁ  shes such as herring (Grzyb and 
Skorkowski 2005).
Patients with COPD have a lower content of high energetic 
phosphates in their skeletal and respiratory muscles compared 
with healthy individuals (Gertz et al 1977; Hughes et al 1983; 
Jakobsson et al 1990). Among athletics, oral supplementation 
with creatine has been used in physical training in short-lasting 
muscle work and is associated with an increase in exercise 
capacity. Besides this effect, supplementation with creatine 
has been showed to increased muscular strength and volume 
(Harris et al 1993). 
In patients with chronic heart failure, creatine supplemen-
tation has shown signiﬁ  cantly increased skeletal muscular 
performance compared with a placebo group (Gordon et al 
1995). Patients with chronic heart failure have similar meta-
bolic changes in their skeletal muscles to patients with COPD 
(Opasich et al 1996). In the present study the aim was to assess 
whether creatine supplementation and exercise training could 
increase physical performance compared with exercise training 
in patients with COPD. 
Materials and methods
Patients
Between January 2001 and March 2003, 23 patients with 
COPD were recruited to the present study. All patients par-
ticipated in the pulmonary rehabilitation program including 
exercise training at the Karolinska University Hospital in Solna 
or at the University Hospital in Linköping. All patients had 
COPD according to the British Thoratic Society guidelines 
(forced expiratory volume in one second [FEV1] < 80% of 
predicted, FEV1/vital capacity [VC] < 70%) (BTS 1997), and 
were all in a clinically stable phase. Patients with sympto-
matic cardiac disease, neurological or orthopedic disability 
with mobility impairments, and unwillingness to participate 
in the study were not included. Of the 23 participants, there 
were 13 women and 10 men, with a mean age of 66 ± 6 (mean 
± SD) years. FEV1 was 1.2 ± 0.6, FEV1 % of predicted was 
43 ± 17 and arterial oxygen partial pressure [PaO2] was 9.6 
± 1.5 kPa.
All patients inhaled short- and long-acting brochodilators, 
13 patients inhaled corticosteroid, two patients had both oral 
and inhaled steroids, and one patient only had oral steroids. 
Four patients were treated with diuretics, nine with oral 
N-acetylcysteine and ﬁ  ve with oral theophylline. The patients’ 
medical treatment was unchanged during the study period. One 
patient had never smoked (COPD caused by alpha-1-antitrypsin 
deﬁ  ciency), four were current smokers, and 19 patients were 
ex-smokers.
The study was approved by the Local Ethics Committee at 
the Karolinska University Hospital (Dnr: 00-404).
Spirometry and arterial blood samples
Spirometry was performed by a Vitalograph Compact C 
(Förbandsmaterial AB, Gothenburg, Sweden). Normal values 
were calculated according to European Coal and Steel Union 
guidelines (ECSU 1983). An arterial blood sample was taken 
with the patient seated and spontaneously breathing air. The 
samples were analyzed within 15 minutes. Both spirometry 
and arterial blood samples were assessed before and after the 
rehabilitation programme.
Pulmonary rehabilitation programme and 
health-related quality of life
The eight-week rehabilitation programme consisted of 
exercise training and education, with two training sessions 
a week supervised by of a specially-trained physiotherapist. 
Each training sessions consisted of eight different exercises: 
ergometer cycling, arm muscle training with dumbbells, ris-
ing from a stool, theraband exercises for the shoulder girdle, 
thigh muscle training with weight cuffs, getting up onto a low 
stool, abdominal muscle training, and ﬂ  exibility exercises for 
the thorax and adjacent joints. 
The aim of the ergometer cycling was to be able to exercise 
without interruption for 30 minutes. The load was chosen by the 
physiotherapist based on the degree of dyspnea and leg fatigue 
rated on a Borg CR-10 scale and/or whether the patient was 
forced to stop pedaling at very short intervals (Borg 1982). The 
maximum tolerated degree of dyspnea was 7 out of 10. The load 
during cycling was increased when the patient could exercise 
without interruption for 30 minutes. Oxygen saturation and heart 
rate were recorded via pulse oximetry before, during, and at the 
end of every ergometer cycling session.
In the other exercises, the patients performed 15 repeti-
tions for each exercise repeated three times. In the exercises 
which required different loads such as weight cuffs, the 
physiotherapist guided the patients to identify the weight that 
after 15 repetitions was so heavy that it could not be lifted 
once more. During the training session, patients were given 
instructions in pursed lips breathing. The length of the 
training sessions varied between 60–75 minutes depending International Journal of COPD 2006:1(4) 447
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on need of recovery between the different exercises. 
During the 8 week programme the patients also took part 
in an educational programme including lung physiology, 
pulmonary disease, breathing techniques, secretion clear-
ance techniques, medications, and nutrition. all patients 
received a home training programme after the training period 
and were encouraged to be physically active in daily life. 
Health-related quality of life was assessed with St George’s 
Respiratory Questionnaire (SGRQ) (Jones et al 1992) at 
baseline and after the training programme. A decrease in 
score indicates a better health-related quality of life and 
a change of 4 units is of clinical relevance according to 
Jones (2002). 
Creatine supplementation
Thirteen patients were randomized to the creatine group and 
ten to the placebo group. There were no differences between 
the groups regarding clinical background data (Table 1). All 
patients received oral and written instructions on how to 
ingest the compound. All involved investigators were blinded 
to patients receiving creatine supplementation. The powder 
(glucose or creatine) was delivered in small test tubes and 
was taken orally during 8 weeks. The dosage of creatine 
was 0.3 g/kg body weight/day during seven days and then 
0.07 g/kg body weight/day during the remaining 7 weeks. The 
patients dissolved the powder in hot liquid. The intake was 
divided in four doses per day during the ﬁ  rst week and one 
dose per day during the remaining weeks. 
On three occasions, at one week from start and at eight 
weeks and two months after the end of the creatine intake, 
the patients collected the urine during 24 hours to get a rough 
indication that the patients had ingested creatine. These data 
were not presented.
Walking tests
The patients performed an Incremental shuttle walking test 
(ISWT) (Singh et al 1992). Before the test and directly after, 
oxygen saturation, heart and breathing rates were measured as 
well as dyspnea and leg fatigue. Oxygen saturation and heart 
rate were measured using pulse oximeters (Model 8500, Nonin 
Medical Inc, MN, USA/Model 512, Novametrix Medical inc. 
Wallingford, CT, USA) (Wahr et al 1995). The patients rated 
their dyspnea and leg fatigue according to a Borg CR-10 scale 
(Borg 1982).  
Depending on the walking distance during the ISWT, walk 
speed was correlated for the Endurance Shuttle Walking Test 
(ESWT) (Revill et al 1999). The patients performed both an 
ISWT and an ESWT at baseline, but only ESWT at the 8 weeks 
follow up after the training programme. 
Measurements of muscle strength 
and fatigue
The grip strength was measured with a Jamar Dynamometer/
Grippit (Jamardynamometer standard, BB44JR, WS Routband 
Comp LTD, Albionmille, Helmshore, Rossendale, UK/Grippit 
type G100, serial number 197100, AB detector, Gothenburg, 
Sweden) at baseline and after 8 weeks. The patients were told 
to squeeze maximally during ﬁ  ve seconds. After resting for one 
minute the patients repeated the test with the same instructions 
for the second and third trial. The mean value of the three trials 
was recorded (Mathiowetz et al 2000). 
In 12 patients (7 women, mean age 63 ± 8 years and 
5 men 70 ± 2 years), maximal voluntary strength and fatigue 
in right knee extensors muscles were assessed; seven from 
the creatine group and ﬁ  ve from the placebo group. Maximal 
voluntary strength and fatigue in right knee extensors muscles 
were measured with an isokinetic dynamic dynamometer 
(Kin-Com 500H, Chattecx Corp., Chattanooga TN, USA) dur-
ing standardized perpetual verbal encouragement (Stahle and 
Tollback 2001). Maximal voluntary concentric strength was 
measured at 30°/s angular velocity in a movement range from 
90° to 30° knee ﬂ  exion. Mean peak torque of the three curves 
with good reproducibility was calculated. After a ﬁ  ve minutes 
rest, muscle fatigue was evaluated by 3 bouts of 30 maximal 
consecutive concentric repetitions at 180°/s angular velocity 
in a movement range from 90° to 30° knee ﬂ  exion (Colliander 
et al 1988). Fatigue was evaluated by calculating the decline in 
strength within and between bouts. Thus, the declines of mean 
peak torque (PT) for repetitions 1–10, 11–20, and 21–30 were 
calculated. Further, the decline of the summed PT per bout was 
calculated and compared between bouts. One learning-session 
Table 1 Patient characteristics at baseline 
  Placebo group  Creatine group
  n = 10  n = 13 
Men/women 4/6  6/7
Age, years  64 ± 6  67 ± 6
FEV1 % pred  42 ± 12  44 ± 21
PaO2, kPa  9.7 ± 1.5  9.5 ± 1.5
PCO2, kPa  5.0 ± 0.7  4.9 ± 0.3
Weight, kg  63 ± 14  72 ± 16
BMI, kg/m2  22 ± 3  25 ± 4
ISWT, m  290 ± 67  305 ± 107
Note: Values are presented as mean ± SD. 
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in one 
second; ISWT, Incremental Shuttle Walking Test; m, metres; PaO2, arterial oxygen 
partial pressure; PCO2, arterial carbon dioxide partial pressure; SD, standard 
deviation. International Journal of COPD 2006:1(4) 448
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Figure 1 Individual walking time during Endurance Shuttle Walking Test (ESWT) for the creatine (n = 13) and the placebo groups (n = 10) before and after creatine/placebo 
supplementation and the training programme. Within the creatine group difference: p < 0.01; within the placebo group difference: p = 0.0741. Creatine group versus placebo 
group (p = 0.8).
was performed at least two days or within one week before the 
actual baseline testing.
Statistics
The primary outcome was physical performance measured 
with ESWT. The sample size was powered as other studies 
showing effects of pulmonary rehabilitation programmes 
(Lacasse et al 1996).
The group results are presented as arithmetical means (m) 
and conﬁ  dence intervals or median and range unless otherwise 
stated. To test differences between groups unpaired Student’s 
t-test and Wilcoxon Rank sum were used, and within group 
analysis by paired wise Student’s t-test.
Results
Effect of creatine supplementation on 
lung function, arterial blood gases,
and body weight 
No signiﬁ  cant changes in FEV1 and arterial blood gases neither 
within or between the creatine and the placebo group before 
or after the training programme were found. Body weight was 
unchanged after creatine supplementation in both groups. 
Effect of creatine supplementation on 
Endurance Shuttle Walking Test and 
Health-Related Quality of Life
Patients with creatine supplementation increased their aver-
age walking time by 61% from 320 (95% conﬁ  dence interval 
[CI] 218.9 to 421.4) to 515 (95% CI 324 to 705.9) seconds 
in ESWT (p < 0.01) after the training programme, while 
the group with placebo treatment increased theirs by 48% 
from 372 (95% CI 177.2 to 567.4) to 552 seconds (95% CI 
276.6 to 828.2) (p = 0.07). The difference in walking time 
(ESWT) between the two groups from baseline and after 8 
weeks training programme was not statistically signiﬁ  cant 
(p = 0.8) (Figure 1).
The patients’ median rated dyspnea directly after the 
ESWT, before and after the 8 week programme, decreased 
signiﬁ  cantly from 7 to 5 (p < 0.05) in the creatine group. In 
the placebo group the dyspnea index decreased from 5 to 4 
(p = 0.28). The median rated leg fatigue tended to decrease 
from 3 to 2 (p = 0.06) in the creatine group (n = 10) and 
from 2 to 0.25 in the placebo group (n = 6) (p = 0.36). In 
comparison between the two groups there was no signiﬁ  cant 
difference in median rated dyspnea or leg fatigue after the 
8 weeks programme. 
Oxygen saturation, heart rate and breathing after the 
8 weeks programme, assessed directly after the ESWT, showed 
no signiﬁ  cant difference within or between the groups. 
Regarding health-related quality of life no signiﬁ  cant dif-
ferences in the various dimensions (symptoms, activity, and 
impacts) or in total score after the training programme were 
found. The dimension of symptom decreased with a signiﬁ  cant 
difference (p < 0.05) within the placebo group since two pa-
tients had 40 units in difference from baseline compared with 
a mean of 7 units change for the rest of the group. The creatine 
group also decreased in this dimension with a mean value of International Journal of COPD 2006:1(4) 449
Creatine supplimentation and physical training in patients with COPD
5 units, but did not reach signiﬁ  cant difference. The change in 
units, at baseline, and after the training programme regarding 
the dimensions and total score are shown in Figure 2. 
Effect of creatine supplementation 
on muscle strength and fatigue
There were no signiﬁ  cant differences in grip strength between 
the creatine group (n = 12) and the placebo group (n = 10) 
before and after the training programme. 
No differences in maximal knee extensor strength within 
or between the creatine (n = 7, p = 0.74) and placebo (n = 5,
p = 0.07) groups before or after the training programme 
(p = 0.08) (Figure 3). Maximal knee extensor strength for 
the total group was 131 Nm (95% CI 106 to 155) and 138 
Nm (95% CI 111 to 165), before and after the training pro-
gramme (p = 0.26). 
The decline in mean and PT during the fatigue tests did 
not differ within or between the groups before or after the 
training programme. The results from the leg muscle fatigue 
test in the creatine group (n = 7) are shown in Figure 4.
All results are summarized in Table 2.
Discussion
The aim of the present study was to investigate whether crea-
tine supplementation may have an additive effect on physical 
performance in COPD patients participating in a pulmonary re-
habilitation programme including exercise training. We failed to 
prove any differences in walking time (ESWT) after the training 
period between the groups receiving creatine supplementation or 
placebo. Our data did not show that exercise training and creatine 
supplementation improved walking time in ESWT in relative to 
exercise training and placebo. 
All patients included in the study were referred from the 
Primary Health Care in Stockholm and Linköping County 
and seemed to be representative for a group of patients with 
moderate to severe COPD. Today the effect of exercise train-
ing in patients with COPD is well established and there are 
several studies including patients with moderate to severe 
stage of COPD showing beneﬁ  ts of pulmonary rehabilitation 
(Wijkstra et al 1994; Donner and Muir 1997; Tiep 1997). When 
we formed our programme we followed the evidence-based 
guidelines as outlined in “Pulmonary rehabilitation” (ACCP/
AACVPR 1997). There were no difﬁ  culties for the patients 
to accomplish the exercise programme and reach the desired 
levels of dyspnea. The ESWT test is a submaximal test of 
physical performance and should therefore reﬂ  ect a person’s 
daily physical performance better than a maximal test. The test 
has also showed sensitivity to changes after exercise training 
in COPD patients (Revill et al 1999).
In the present study, ESWT improved in both groups. 
However, the improvement was signiﬁ  cant only in the creatine 
group. There was no signiﬁ  cant difference when comparing the 
results of the ESWT between the groups. Hence, we failed to 
show any beneﬁ  t of creatine supplementation in combination 
with exercise training. 
In healthy subjects an increase of 25%–30% of total 
creatine concentration in the muscles was found after oral 
creatine supplementation, as well as a signiﬁ  cant increase 
in maximal short-lasting muscle work after oral creatine 
supplementation. The size of the increase in strength power 
was approximately 4%–6% (Balsom et al 1993). 
Gordon and colleagues (1995) found significantly 
increased skeletal muscular performance in patients with 
chronic heart failure compared with a placebo group after 
oral supplementation of creatine during ten days without 
any exercise training. They concluded that both patients 
with heart failure and healthy individuals with low levels 
of creatine in the muscles show better muscle function after 
oral supplementation. 
Studies of skeletal muscle metabolite concentrations in 
leg muscle of patients with COPD have shown deranged mus-
cle metabolism with decreased concentrations of ATP and 
creatine phosphate (Jakobsson and Jorfeldt 1995). A positive 
effect in physical performance was therefore expected when 
creatine was supplemented to training.
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A recently reported study, also investigating the effect of 
creatine supplementation on physical performance in patients 
with COPD, Fuld and colleagues (2005), reports an increase 
in fat-free-mass, upper and lower limb muscle strength and 
endurance, but no improvement in whole body exercise 
capacity. In this study the patients had a loading phase of 
supplements for 14 days, then a maintenance phase during 
a 10 week training programme. 
In contrary to Fuld and colleagues (2005) our patients started 
supplementation with creatine/placebo and exercise training at International Journal of COPD 2006:1(4) 451
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the same time with one week higher intake of creatine and then 
a maintaining phase during the rest of the training period, ie, 
seven weeks. The quantity, duration, and intensity of the training 
sessions seem to be equal to Fuld´s study except for the fact that 
we did not provide a home training program to the participants 
during the exercise programme. 
The lacking effect in our study may be due to the fact that 
we used the submaximal performance test and that the sample 
size in measuring lower limb muscle strength was low. Also, 
our programme was not formed to train speciﬁ  ed muscle 
groups. Furthermore, we have no data of skeletal muscle meta-
bolic concentration to show that oral creatine supplementation 
was accompanied by increased concentration of high-energy 
phosphates in the leg muscles. 
The questionnaire for measuring health-related quality of 
life (SGRQ) was found suitable for the group of COPD-patients 
included in the present study. That the degree of physical ability 
affects the quality of life, and that rehabilitation programmes for 
COPD patients have a positive effect on physical performance 
and quality of life has been shown by Jones and colleagues 
(1992). In the creatine group, all three dimensions (symptoms, 
activity and impact) and the total score in SGRQ changed in a 
positive direction, but did not reach clinical signiﬁ  cance (Jones 
2002). In the placebo group there was a surprisingly large 
improvement in the dimension of symptoms (15 units) and when 
we analyzed the data we found that two patients had 40 units 
in difference from baseline compared with a mean of 7 units 
change for the rest of the group (n = 6). We speculate that these 
two patients have had an exacerbation close to baseline and 
recovered during the training programme. 
There is to our knowledge only one study published inves-
tigating the effects of creatine supplementation in patients with 
COPD (Fuld et al 2005). The results in the present study failed 
to show an effect of oral creatine supplementation in contrast 
to Fuld and colleagues (2005). Further research in this ﬁ  eld to 
ﬁ  nd individual modalities of treatment for patients with COPD 
is needed (Grifﬁ  ths and Proud 2005). 
Our conclusion is that because COPD patients are a very 
heterogeneous group, they could probably respond very dif-
ferently to oral creatine supplementation and we need larger 
studies to ﬁ  nd whether oral creatine supplementation is of any 
beneﬁ  t for patients with COPD or not.
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